Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015',

In this issue

Home Eurosurveillance Edition  2013: Volume 18/ Issue 17 Article 4
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 18, Issue 17, 25 April 2013
Virus-host interactions and the unusual age and sex distribution of human cases of influenza A(H7N9) in China, April 2013
  1. British Columbia Centre for Disease Control, Vancouver, Canada
  2. University of British Columbia, Vancouver, Canada
  3. Institut National de Santé Publique du Québec (National Institute of Health of Quebec), Québec, Canada
  4. Laval University, Quebec, Canada
  5. Centre Hospitalier Universitaire de Québec (University Hospital Centre of Quebec), Québec, Canada

Citation style for this article: Skowronski DM, Janjua NZ, Kwindt TL, De Serres G. Virus-host interactions and the unusual age and sex distribution of human cases of influenza A(H7N9) in China, April 2013 . Euro Surveill. 2013;18(17):pii=20465. Available online:
Date of submission: 24 April 2013

To the editor: Over the past two weeks, Eurosurveillance has published several timely papers related to the emergence of a new influenza A(H7N9) virus affecting humans in China [1-3]. Genetic studies by Kageyama et al. [1] and Jongens et al. [2] assessed evidence in the genome for virus origin, adaptation and virulence, and a paper by Corman et al. [3] described real-time reverse-transcription PCR assays for specific virus diagnosis. While these are important aspects of novel virus characterisation and detection, the accrual of over 100 human cases now also affords opportunity to consider evolving epidemiologic patterns as part of population risk assessment.

Perhaps the most intriguing impression to date from available surveillance findings has been the unexpected age/sex distribution of reported influenza A(H7N9) cases. The age range spans from 2 to 91 years but two thirds of influenza A(H7N9) cases have been 50 years of age or older and two thirds have been male (Table) [4,5]. Illness severity, with a substantial case fatality of 20%, shows a similar age/sex profile (Table) [4,5]. Unlike the pattern observed for influenza A(H5N1), children, both boys and girls and notably the school-aged, are under-represented among influenza A(H7N9) detections. Among the first 100 adult influenza A(H7N9) cases, men and women were equally represented in the youngest age category 20–34 years, but men were 2–3-fold more frequent than women in older age groups (Table). Furthermore, compared with women 20–34 years of age, women 50–64 and 65–79 years were each twice as frequent among influenza A(H7N9) detections. Conversely, men 50–64 and 65–79 years are each 4–5-fold more frequent among influenza A(H7N9) detections than men 20–34 years of age. While being careful not to over-interpret early surveillance data, what hypotheses might be invoked to explain that pattern?

Table. Human cases of influenza A(H7N9) and deaths by age group and sex, China, as of 23 April 2013 (n=109)a

Disease occurrence is the result of the classic interaction triad of agent–host–environment. Environmental factors such as differences in poultry exposure due to socio-cultural behaviours and host factors such as healthcare-seeking behaviour or underlying comorbid conditions have been postulated to explain these early influenza A(H7N9) surveillance signals [6,7]. However, hypotheses should also include the additional perspective of agent (i.e. virus)–host interactions. Immunological profiles by age likely reflect accumulated lifetime opportunities for influenza virus exposure, leaving intricate imprints that may positively or negatively modulate subsequent risk. We have illustrated this immunological complexity at the population level for influenza, showing variation in age-specific cross-reactive antibody levels to previously emerging influenza A(H1N1)pdm09 virus [8] and more recently to the emerging (swine-origin) influenza A(H3N2)v, probably reflecting complex cohort effects based on differential prime/boost exposures to influenza variants by age [9].

That pre-existing immunity can differentially modulate the infection process for novel pathogens may be relevant in understanding the differing age distributions of the emerging influenza A(H5N1) versus A(H7N9) viruses [6,7]. Anti-neuraminidase (N1) antibodies induced by cumulative influenza A(H1N1) lifetime exposures may have a role in mitigating risk and severity of influenza A(H5N1) infection [10-13] in older individuals accounting for its more youthful profile to date [4-7]. In contrast, for influenza A(H7N9) we may anticipate that anti-N9 antibodies would be less prevalent overall in the population. Other population immunological effects of the 2009 influenza A(H1N1) pandemic, which affected predominantly young people, such as cross-reactive T-cell responses to generally conserved internal virus proteins [14] or memory B cell responses to shared epitopes within group 1 (i.e. H1, H5) versus group 2 (i.e. H3, H7) subtypes [15] may also need to be considered as factors that influence influenza A(H5N1) and A(H7N9) age profiles.

At this stage, we should also stay open to the possibility that pre-existing cross-reactive antibodies may actually facilitate the viral infection process, a phenomenon best recognised for dengue through the mechanism of antibody dependent enhancement (ADE) [16,17]. ADE is thought to occur when low-levels of weakly heterotypic, cross-reactive but not cross-protective, antibodies generated by past exposure to virus antigen, e.g. through prior infection or immunisation, form bridging complexes to facilitate uptake and replication of related but non-identical variants [16-18]. The possibility of ADE in influenza has long been and remains the subject of intense interest among experts [19,20], for which there may recently be indirect evidence. Early during the 2009 influenza pandemic, we described a potentially important interaction between seasonal and novel emerging influenza virus, notably an approximate doubling of the likelihood of medically-attended pandemic influenza A(H1N1) illness among people previously administered seasonal influenza vaccine that contained virus antigenically related but distant from the emerging influenza A(H1N1)pdm09 strain [18]. In a follow-up experiment, vaccinated ferrets showed higher lung virus titres and greater illness severity after influenza A(H1N1)pdm09 challenge than influenza-naïve animals [21]. In swine, disease exacerbation has also been observed following heterologous challenge [22-24]. ADE was one of the proposed (but unproven) hypotheses to explain the unexpected findings from Canada during the 2009 pandemic [18]. The possible relevance of weakly cross-reactive antibodies in facilitating infection due to other emerging influenza viruses with pandemic potential may therefore warrant further consideration.

In that regard, older Chinese men may not only have a greater likelihood of current poultry/bird exposure, to explain their disproportionate representation among influenza A(H7N9) cases, but also a greater total sum of lifetime avian influenza exposures potentially contributing to cross-reactive H7 antibody. Few serosurveys to assess H7 antibodies in the population of China are available in the English language, and none has yet been sufficiently powered to compare this by age or sex [25-28]. In a serosurvey conducted 20 years ago in central China (Nanchang), 25% of 100 samples collected from women who raised pigs were found by ELISA to have antibodies to purified H7 antigen [25]. In a more recent serosurvey conducted in 2006–08 in northern China, 5–10% of ca. 1,000 farmer families and poultry workers aged 5–87 years had detectable but low-level antibodies (titre of at least 1:20 but not exceeding 1:40) to influenza (H7N1) in a modified haemagglutination inhibition (HI) assay using horse erythrocytes [26]. In 2011, none of >1,500 duck-related workers in Beijing aged 14–71 years had influenza (H7N2) or (H5N1) titres exceeding 1:40 by modified HI, although seropositivity to influenza (H9N2) was more prevalent, particularly among adults older than 50 years of age in whom the rate of seropositivity was four-fold higher than among younger participants [28].

Although the detection of antibodies to H7 subtype viruses has proved challenging even among culture-confirmed cases [29-35], serosurveys to compare cross-reactive antibodies and neutralising effects by multiple assays and by age group could be important, not only to inform possible protection, but also to explore patterns of enhanced risk in influenza A(H7N9) affected areas and more broadly elsewhere to inform risk assessment. Certain immunological effects, including ADE as it pertains to influenza, may yet be speculative. At this early stage of trying to understand the unexpected epidemiological patterns of an emerging pathogen, however, it is prudent for the global scientific and public health community to consider all possibilities within the full virus–host–environment paradigm. 

Authors' contributions
All authors contributed to the writing, review and final approval of this letter.

Conflict of interest
GDS has received research grants from GlaxoSmithKline (GSK) and Sanofi Pasteur and participated in an ad hoc GSK advisory board meeting for an unrelated issue for which travel expenses were reimbursed. No other authors have competing interests to declare.


  1. Kageyama T, Fujisaki S, Takashita E, Xu H, Yamada S, Uchida Y, et al. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill. 2013;18(15):pii=20453. Available from: PMid:23594575.
  2. Jonges M, Meijer A, Fouchier RA, Koch G, Li J, Pan JC, et al. Guiding outbreak management by the use of influenza A(H7Nx) virus sequence analysis. Euro Surveill. 2013;18(16):pii=20460. Available from: PMid:23611030.
  3. Corman VM, Eickmann M, Landt O, Bleicker T, Brünink S, Eschbach-Bludau M, et al. Specific detection by real-time reverse-transcription PCR assays of a novel avian influenza A(H7N9) strain associated with human spillover infections in China. Euro Surveill. 2013;18(16):pii=20461. Available from: PMid:23611031. 
  4. World Health Organization (WHO). Avian influenza A(H7N9) virus. Geneva: WHO. [Accessed 23 Apr 2013]. Available from:
  5. Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, et al Preliminary Report: Epidemiology of the Avian Influenza A (H7N9) Outbreak in China. N Engl J Med. 24 Apr 2013, DOI: 10.1056/NEJMoa1304617.
  6. Arima Y, Zu R, Murhekar M, Vong S, Shimada T, the World Health Organization Regional Office for the Western Pacific Event Management Team. Human infections with avian influenza A(H7N9) virus in China: preliminary assessments of the age and sex distribution. WPSAR. 2013;4(2). Doi. 10.5365/wpsar.2013.4.2.005. Available from:
  7. University of Minnesota. Center for Infectious Disease Research & Policy (CIDRAP). H7N9 mystery: why does age profile tilt older? Minneapolis: CIDRAP. [Accessed 23 Apr 2013]. Available from:  
  8. Skowronski DM, Hottes TS, McElhaney JE, Janjua NZ, Sabaiduc S, Chan T, et al. Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J Infect Dis. 2011;203(2):158-67. PMid:21288814. PMCid:3071066.
  9. Skowronski DM, Janjua NZ, De Serres G, Purych D, Gilca V, Scheifele DW, et al. Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). J Infect Dis. 2012; 206(12):1852-61. PMid:22872731.
  10. Easterbrook JD, Schwartzman LM, Gao J, Kash JC, Morens DM, Couzens L, et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containin 2009 pandemic H1N1 neuraminidase in mice. Virology. 2012;432(1):39-44. PMid:22727831.
  11. Chen Z, Kim L Subbarao K, Jin H. The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA0 antibodies that cross-react with the NA of H5N1 viruses in ferrets. Vaccine. 2012;30(15):2516-22. PMid:22330124.
  12. Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G, Katz JM, et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol. 2009;83(11):5726-34. PMid:19321609. PMCid:2681940.
  13. Rockman S, Brown LE, Barr IG, Gilbertson B, Lowther S, Kachurin A, et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J Virol. 2013;87(6):3053-61. PMid:23283953.
  14. Hillaire MLB, Vogelzang-van Trierum SE, Kreijtz JHCM, de Mutsert G, Fouchier RAM, Osterhaus ADME, et al. Human T-cells directed to seasonal influenza A virus cross-react with 2009 pandemic influenza A (H1N1) and swine-origin triple-reassortant H3N2 influenza viruses. J Gen Virol. 2013;94(Pt 3):583-92. PMid:23152369.
  15. Mahallawi WH, Kasbekar AV, McCormick MS, Hoschler K, Temperton N, Leong SC, et al. 2009 H1N1 infection primes for immunological memory in human nasal-associated lymphoid tissue that offers cross-reactive immunity to H1N1 and avian H5N1 viruses. J Virol. 2013 Mar 6. [Epub ahead of print].
  16. Stephenson JR. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ. 2005;83(4):308-14. PMid:15868023. PMCid:2626214.
  17. Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, Flanagan A, et al. An in-depth analysis of original antigenic sin in dengue virus infection. J Virol. 2011;85(1):410-21. PMid:20980526. PMCid:3014204.
  18. Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, Hottes TS, et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: Four observational studies from Canada. PLoS Med. 2010;7(4):e1000258. PMid:20386731. PMCid:2850386.
  19. Gotoff R, Tamura M, Janus J, Thompson J, Wright P, Ennis FA. Primary influenza A virus infection induces cross-reactive antibodies that enhance uptake of virus into Fc receptor-bearing cells. J Infect Dis. 1994;169(1):200-3. PMid:8277183.
  20. Dutry I, Yen H, Lee H, Peiris M, Jaume M. Antibody-dependent enhancement (ADE) of infection and its possible role in the pathogenesis of influenza. BMC Proc. 2011;5(Suppl 1):P62.
  21. Skowronski DM, Hamelin ME, De Serres G, Janjua NZ, Li G, Bouhy X, et al. Prior receipt of 2008-09 trivalent inactivated influenza vaccine increases pandemic H1N1 severity in ferrets: randomized double-blind placebo-controlled experiment. Abstract and poster to 52nd ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy). San Francisco, CA, USA. 9-12 Sep 2012.
  22. Vincent AL, Lager KM, Janke BH, Gramer MR, Richt JA. Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine. Vet Microbiol. 2008;126(4):310–23. PMid:17719188.
  23. Gauger PC, Vincent AL, Loving CL, Lager KM, Janke BH, Kehrli ME Jr., et al. Enhanced pneumonia and disease in pigs vaccinated with an inactivated human-like (δ-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1 influenza virus. Vaccine. 2011;29(15):2712-9. PMid:21310191.
  24. Gauger PC, Vincent AL, Loving CL, Henningson JN, Lager KM, Janke BH, et al. Kinetics of lung lesion development and pro-inflammatory cytokine response in pigs with vaccine-associated enhanced respiratory disease induced by challenge with pandemic (2009) A/H1N1 influenza virus. Vet Pathol.2012; 49(6):900-12. PMid:22461226.
  25. Zhou N, He S, Zhang T, Zou W, Shu L, Sharp GB, et al. Influenza infection in humans and pigs in southeastern China. Arch Virol. 1996;141(3-4):649-61. PMid:8645101.
  26. Jia N, de Vlas SJ, Liu Y-X, Zhang J-S, Zhan L, Dang R-L, et al. Serological reports of human infections of H7 and H9 avian influenza viruses in northern China. J Clin Virol. 2009;44(3):225-29. PMid:19186101.
  27. Liu Y, Lu EJ, Wang YL, Di B, Li TG, Zhou Y, et al. Avian influenza virus infection in people occupied in poultry fields in Guangzhou city. Zhonghua Liu Xing Bing Xue Za Zhi. 2009;30(11):1111-3. Chinese. PMid:20193575.
  28. Yang P, Ma C, Shi W, Cui S, Lu G, Peng X, et al. A serological survey of antibodies to H5, H7 and H9 avian influenza viruses amongst the duck-related workers in Beijing, China. PLoS One. 2012;7(11):e50770. PMid:23226380. PMCid:3511333.
  29. Bosman A, Mulder YM, de Leeuw JRJ, Meijer A, Du Ry van Beest Holle M, Kamst RA, et al. Executive summary avian flu epidemic 2003: public health consequences. Bilthoven: RIVM; 2004. Rep 630940004/2004. Available from:
  30. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A. 2004;101(5):1356-61. PMid:14745020. PMCid:337057.
  31. Stephenson I, Wood JM, Nicholson KG, Zambon MC. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza hemagglutinin. J Med Virol. 2003;70(3):391-8. PMid:12767002.
  32. Du Ry van Beest Holle M, Meijer A, Koopmans M, de Jager CM. Human-to-human transmission of avian influenza A/H7N7, The Netherlands, 2003. Euro Surveill. 2005;10(12):pii=584. Available from: PMid:16371696.
  33. Meijer A, Bosman A, van de Kamp EE, Wilbrink B, Du Ry van Beest Holle M, Koopmans M. Measurement of antibodies to avian influenza virus A (H7N7) in humans by hemagglutination inhibition test. J Virol Methods. 2006;132(1-2):113-20. PMid:16271401.
  34. Skowronski DM, Li Y, Tweed SA, Tam TWS, Petric M, David ST, et al. Protective measures and human antibody response during an avian influenza H7N3 outbreak in poultry in British Columbia, Canada. CMAJ. 2007;176(1):47-53. PMid:17200390. PMCid:1764568.
  35. Tweed SA, Skowronski DM, David ST, Larder A, Petric M, Lees W, et al. Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis. 2004;10(12):2196-9. PMid:15663860. PMCid:3323407.

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.